STOCK TITAN
  1. Home
  2. Sec-filings
  3. RMD
  4. [Form 4] RESMED INC Insider Trading Activity

ResMed (RMD) CEO sells 8,011 shares at $249.7532; exercises

ResMed Inc. (RMD) reported insider activity by Chairman and CEO Michael J. Farrell.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported insider activity by Chairman and CEO Michael J. Farrell. On 11/07/2025, he exercised stock options at $101.64 for 983 shares and 7,028 shares, and sold 8,011 shares at a weighted average price of $249.7532 (multiple trades between $248.13 and $251.46). The transactions were made pursuant to a Rule 10b5-1 plan adopted October 31, 2024.

Following these transactions, Farrell beneficially owned 467,866 shares directly and 2,090 shares indirectly via the Lisette and Michael Farrell Family Trust. Notes indicate options first became exercisable on 11/11/2019 and vest one-third per year, with expiration on 11/14/2025, and that holdings include 74.3412 shares purchased through the Employee Stock Purchase Plan on October 31, 2025.

Positive

  • None.

Negative

  • None.
Insider Farrell Michael J.
Role Chairman and CEO
Sold 8,011 shs ($2.00M)
Approx. gross sale proceeds $2.00M
Approx. exercise cost $814K
Approx. pre-tax spread $1.19M
Type Security Shares Price Value
Exercise ResMed Common Stock Options 983 $0.00 $0.00
Exercise ResMed Common Stock Options 7,028 $0.00 $0.00
Exercise ResMed Common Stock 983 $101.64 $100K
Exercise ResMed Common Stock 7,028 $101.64 $714K
Sale ResMed Common Stock 8,011 $249.7532 $2.00M
holding ResMed Common Stock -- -- --
Holdings After Transaction: ResMed Common Stock Options — 0 contracts (Direct); ResMed Common Stock — 467,866 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (4)
  1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
  2. F2. Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
  3. F3. This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price.
  4. F4. Represents date options first become exercisable. Options vest 1/3 per year.

FAQ

What insider transaction did RMD’s CEO report on 11/07/2025?
He exercised options at $101.64 for 983 and 7,028 shares, and sold 8,011 shares at a weighted average of $249.7532.

Was the RMD CEO’s trade under a 10b5-1 plan?
Yes. Transactions were made under a Rule 10b5-1 plan adopted on October 31, 2024.

How many RMD shares did the CEO own after the transactions?
Beneficial ownership was 467,866 shares directly and 2,090 shares indirectly via the family trust.

What price range were the RMD share sales executed at?
Multiple trades occurred between $248.13 and $251.46, with a weighted average of $249.7532.

What were the terms of the exercised RMD options?
Options had an exercise price of $101.64, first became exercisable on 11/11/2019, vest one-third per year, and expire on 11/14/2025.

Do the reported holdings include ESPP purchases?
Yes. Holdings include 74.3412 shares acquired through the Employee Stock Purchase Plan on October 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farrell Michael J.
(Last) (First) (Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD
(Street)
SAN DIEGO CA 92123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ResMed Common Stock 11/07/2025 M(1) 983 A $101.64 468,849(2) D
ResMed Common Stock 11/07/2025 M(1) 7,028 A $101.64 475,877 D
ResMed Common Stock 11/07/2025 S(1) 8,011 D $249.7532(3) 467,866 D
ResMed Common Stock 2,090 I Lisette and Michael Farrell Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
ResMed Common Stock Options $101.64 11/07/2025 M(1) 983 11/11/2019(4) 11/14/2025 ResMed Common Stock 983 $0 7,028 D
ResMed Common Stock Options $101.64 11/07/2025 M(1) 7,028 11/11/2019(4) 11/14/2025 ResMed Common Stock 7,028 $0 0 D
Explanation of Responses:
1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
3. This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price.
4. Represents date options first become exercisable. Options vest 1/3 per year.
Michael J. Farrell, Chairman and CEO 11/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR